Eur J Clin Microbiol Infect Dis

1. ROTUNDO S, Serapide F, Guido G, Di Gennaro F, et al
   Is the unavailability of rifapentine holding back the end TB strategy in Europe? Implication for tuberculosis control among migrants and refugees.
   Eur J Clin Microbiol Infect Dis. 2025 Dec 16. doi: 10.1007/s10096-025-05304.
   

   >> Share

   
   

   
   Eur Respir J

2. BERANGER A, Solans BP, Miyakawa R, McIlleron H, et al
   Efficacy of isoniazid in pediatric tuberculosis: an individual participant data meta-analysis.
   Eur Respir J. 2025 Dec 18:2501046. doi: 10.1183/13993003.01046-2025.
   

   >> Share

   
   

   
   Int J Tuberc Lung Dis

3. HARRIES AD, Kumar AMV, Nair D, Satyanarayana S, et al
   Operational research to End TB: 2(nd) edition of the Union's Guide to operational research.
   Int J Tuberc Lung Dis. 2025;29:431-433.
   

   >> Share

   
   
4. CASTELLINO LM, Nguyen S, Cobb S, Sreeramoju PV, et al
   Identifying MTB-exposed homeless persons with an electronic health record alert: a safety-net health system's experience.
   Int J Tuberc Lung Dis. 2025;29:441-446.
   

   >> Share

   
   
5. SHARMA S, Patankar S, Becerra MC, Bhalla M, et al
   Yield of a contact investigation among children living with drug-resistant TB patients.
   Int J Tuberc Lung Dis. 2025;29:455-461.
   

   >> Share

   
   
6. PERUMAL R, Pillay S, Bagratee N, Tulsi J, et al
   Anatomical and functional characteristics of symptomatic post-TB lung disease.
   Int J Tuberc Lung Dis. 2025;29:434-440.
   

   >> Share

   
   
7. SINGH S, Boorgula GD, Galvez RA, Heysell SK, et al
   Mycobacteria susceptibility to epetraborole: how far can it go?
   Int J Tuberc Lung Dis. 2025;29:447-454.
   

   >> Share

   
   
8. KODAMA T, Sasaki Y, Tsuyuguchi K, Okumura M, et al
   Clinical outcomes of linezolid-related adverse events in patients with multidrug-resistant TB.
   Int J Tuberc Lung Dis. 2025;29:462-468.
   

   >> Share

   
   

   
   J Antimicrob Chemother

9. UEAPHONGSUKKIT T, Udomkarnjananun S, Vanichanan J, Jutivorakool K, et al
   Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients.
   J Antimicrob Chemother. 2025 Dec 16:dkaf439. doi: 10.1093.
   

   >> Share

   
   

   
   Lancet

10. HUI D, Sahu S, Ditiu L, Marais BJ, et al
    Global tuberculosis response off track: urgent priorities to end the world's top infectious killer.
    Lancet. 2025 Dec 11:S0140-6736(25)02433-X. doi: 10.1016/S0140-6736(25)02433.
    

    >> Share

    
    

    
    N Engl J Med

11. MEYA DB, Cresswell FV, Dai B, Engen N, et al
    Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.
    N Engl J Med. 2025;393:2434-2446.
    

    >> Share

    
    

    
    PLoS One

12. DANSO EK, Asare P, Tetteh AY, Tetteh P, et al
    Mycobacterium tuberculosis complex lineages and drug resistance patterns among tuberculosis patients with or without diabetes mellitus in southern Ghana.
    PLoS One. 2025;20:e0338498.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share